Core Insights - Kestra Medical Technologies reported a strong financial performance for Q2 FY26, achieving a revenue growth of 53% and expanding gross margin to over 50% [2][7] Financial Performance - The company generated revenue of $22.6 million in Q2 FY26, marking a 53% increase compared to the same period last year [7][8] - Gross profit reached $11.4 million, up from $5.8 million in the prior year, with gross margin expanding to 50.6% from 39.6% [8] - GAAP operating expenses were $43.2 million, which included $1.0 million of non-recurring costs, compared to $25.0 million in the prior year [8] - The net loss for Q2 FY26 was $32.8 million, compared to a net loss of $20.6 million in the prior year [8] Operational Highlights - The number of prescriptions written for the ASSURE® system increased by 54% year-over-year, totaling 4,696 prescriptions [8] - Revenue growth was attributed to higher market share, expansion of the wearable defibrillator market, and improvements in revenue cycle management [8] Future Guidance - Kestra has raised its FY26 revenue guidance to $91 million, representing a growth of 52% compared to FY25, up from previous guidance of $88 million [5][7] Cash Position - As of October 31, 2025, the company had cash and cash equivalents totaling $175 million, not including $148 million from a recent equity offering [8]

Core Viewpoint - Kestra Medical Technologies, Ltd. is set to report its second quarter fiscal 2026 financial results on December 11, 2025, with a conference call scheduled for 4:30 p.m. Eastern Time [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company specializing in wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular disease through innovative monitoring and therapeutic technologies [3]. - The company's technologies are designed to be intuitive, intelligent, and connected, reflecting its commitment to transforming healthcare delivery [3]. Conference Call Details - A live and archived webcast of the upcoming conference call will be accessible in the "Events" section of the investor relations website, with participants encouraged to register 10 minutes prior to the call [2].

Core Viewpoint - Kestra Medical Technologies, Ltd. has announced an upsized underwritten public offering of 6,000,000 common shares priced at $23.00 per share, aiming for gross proceeds of $138 million before expenses [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company focused on wearable medical devices and digital healthcare, specifically targeting improvements in patient outcomes for cardiovascular diseases through innovative monitoring and therapeutic technologies [6]. Offering Details - The offering is expected to close on December 4, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 900,000 common shares at the public offering price [1]. - The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities as bookrunners [2].

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offerin ...

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025. “Revenue is expected to grow by over 50% in the second quarter and continues to exceed our FY26 plan, reflecting sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,” said Brian Webster, President and Chief ...

Summary of Kestra Medical Technologies Conference Call Company Overview - **Company**: Kestra Medical Technologies (NasdaqGS:KMTS) - **Industry**: Medical Technology, specifically focusing on wearable cardiac devices Key Points and Arguments Recent Developments - Kestra Medical went public in early March 2025 and has shown strong commercial momentum, reflected in their performance in the first fiscal quarter [4][5] - The company presented significant post-approval study results for their Assure wearable cardioverter-defibrillator (WCD) at the American Heart Association conference [5][6] Study Results and Market Impact - The post-approval study involved over 21,000 patients and met primary and secondary endpoints, enhancing the company's credibility with regulators and in the market [7][8] - The data is expected to facilitate competitive positioning against rivals, particularly in securing market share [8][9] - Currently, only about 1 in 7 eligible patients are prescribed wearable defibrillators, indicating a substantial opportunity for market expansion [9][10] - The total addressable market (TAM) is approximately 850,000 patients, with Kestra currently serving around 120,000 [10] Competitive Landscape - The study results are anticipated to elevate the entire category of wearable defibrillators, potentially leading to stronger clinical guidelines [9][10] - Competitor ZOLL is expected to face challenges in countering Kestra's new data, which is the largest dataset available in the market [20][21] - Kestra's sales team is optimistic about leveraging the new data to secure new accounts and penetrate existing ones more effectively [21][22] Commercial Strategy - Kestra is building a direct-to-cardiology sales force, focusing on high-prescribing physicians and areas with strong payer coverage [31][32] - The company employs a unique commercial execution model that includes contract partners for patient fittings, allowing for scalable growth [33][34] - The ramp-up period for new territories is approximately six months, with existing reps showing continued productivity improvements [35][36] Revenue Conversion and Market Growth - The company reported a conversion rate of 44% for Assure prescriptions into revenue, with expectations for gradual improvement [37][38] - Factors influencing conversion rates include the ability to convert prescriptions into fittings and claims, with Kestra currently achieving an 85% fill rate compared to ZOLL's high 70s [41][42] - Market growth assumptions are based on historical data, with an expected annual growth rate of around 8% [25][26] Future Outlook and Innovation - Kestra is committed to innovation, with a robust R&D pipeline and multiple platforms for future product development [48][49] - The company aims to maintain its competitive edge by continuously extending product differentiation [51] Guidance and Market Position - Kestra emphasizes solid execution and credibility as key components of its guidance philosophy, aiming to consistently beat and raise expectations [58][59] - The company is on track to double its sales force, with plans to assess performance before accelerating further [62][63] Additional Important Insights - The company has a strong foundation due to its history as a spinout from established entities, benefiting from mature systems and supply chains [53][54] - The management is cautious yet optimistic about the future, focusing on leveraging recent data to drive growth and market penetration [64][65]

Core Insights - Kestra Medical Technologies announced positive primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), confirming the safety and effectiveness of the ASSURE WCD in clinical practice [1][2][3] Study Overview - ACE-PAS is the largest prospective real-world study of wearable defibrillators, enrolling 21,612 patients across the U.S. from November 2021 to July 2025 [6] - The study provides contemporary data on the risk of life-threatening ventricular tachycardia and fibrillation in patients with reduced cardiac function [2] Effectiveness and Safety - The primary effectiveness endpoint was achieved with a 100% successful conversion rate for ventricular tachycardia and fibrillation events, exceeding the prespecified performance goal [5] - The study met its primary safety endpoint, reporting an inappropriate-shock rate of 0.0065 per patient-month, confirming a strong safety profile [5] - 94% of patients experienced no false positive shock alarms, enhancing user confidence [5] Patient Protection and Compliance - 2.6% of patients experienced at least one life-threatening VT/VF event within a few months, underscoring the importance of the ASSURE WCD for vulnerable populations [5] - The device detected high-rate atrial fibrillation in 4.2% of patients, with 35% previously undiagnosed, and severe bradycardia/asystole in 0.3%, allowing for timely intervention [5] - Patients wore the device for a median of over 23 hours per day, with one-third continuing use beyond 90 days, indicating high compliance in real-world settings [5] Implications for Clinical Practice - The results of ACE-PAS may inform future updates to clinical practice regarding the identification and protection of patients at early risk of sudden cardiac death [3] - The study emphasizes the critical role of wearable device monitoring and therapy in managing sudden cardiac arrest risk [3]

Core Insights - Kestra Medical Technologies, Ltd. is participating in the American Heart Association (AHA) Scientific Sessions 2025, highlighting its commitment to advancing cardiac care through innovative technology [1] - The company will present primary results from the ACE-PAS Trial, which evaluates a next-generation wearable cardioverter defibrillator system, emphasizing its significance in real-world clinical applications [2][3] Company Overview - Kestra Medical Technologies focuses on wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular disease through connected monitoring and therapeutic interventions [6] Study Details - The ACE-PAS Trial is the largest prospective study of its kind, enrolling over 20,000 patients in the U.S. to assess the effectiveness and safety of the wearable cardioverter defibrillator [3] - Key endpoints of the study include overall shock conversion success, inappropriate shock rate, first shock conversion success, median daily wear time, and false alarm rate [3] Industry Impact - The selection of the ACE-PAS study for a late-breaking presentation at AHA underscores the growing recognition of wearable defibrillator therapy and its role in enhancing clinical insights for cardiac recovery [4] - Kestra's innovations are positioned to redefine the integration of wearable monitoring and therapy within connected care and digital health, aiming to optimize patient protection and recovery [4] Event Participation - At the AHA conference, Kestra will also host live demonstrations and discussions, showcasing its leadership in data-driven solutions for cardiac recovery [5]

Core Insights - Kestra Medical Technologies, Ltd. is scheduled to present at the Stifel 2025 Healthcare Conference on November 11, 2025, at 3:20 p.m. Eastern Time [1] - The company focuses on wearable medical devices and digital healthcare aimed at improving patient outcomes in cardiovascular disease [2] Company Overview - Kestra Medical Technologies is a commercial-stage company that utilizes monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected [2] - The company's mission is to transform patient outcomes specifically in the area of cardiovascular disease [2]

Core Insights - Kestra Medical Technologies, Ltd. has appointed Timothy Moran as Chief Business Officer, effective November 3, 2025, to oversee various strategic and operational aspects of the company [1][2] Company Overview - Kestra Medical Technologies is a commercial-stage company focused on wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular disease through innovative monitoring and therapeutic technologies [4] Leadership Appointment - Timothy Moran brings over 25 years of experience in medtech, having previously served as President and CEO at Avertix Medical, where he launched a first-to-market implantable cardiac device [2] - Moran's expertise in cardiac and heart failure innovation is expected to enhance Kestra's business strategy and partnerships with payors and providers [2][3] Strategic Goals - The company aims to accelerate the adoption of its Cardiac Recovery System® platform and expand its business strategy under Moran's leadership [2][3] - Moran expressed enthusiasm about joining Kestra during a critical growth phase, emphasizing the company's commitment to innovation and patient protection [3]